| [1] |
Sassa N. Retroperitoneal tumors: Review of diagnosis and management[J]. Int J Urol, 2020, 27(12): 1058-1070.
|
| [2] |
Mack T, Purgina B. Updates in pathology for retroperitoneal soft tissue sarcoma[J]. Curr Oncol, 2022, 29: 6400-6418.
|
| [3] |
罗成华. 中国腹膜后肿瘤诊治专家共识(2019版)[J]. 中华肿瘤杂志, 2019, 5(1): 728-733.
|
| [4] |
Improta L, Tzanis D, Bouhadiba T, et al. Overview of primary adult retroperitoneal tumours[J]. Eur J Surg Oncol, 2020, 46: 1573-1579.
|
| [5] |
Sassa N, Yokoyama Y, Nishida Y, et al. Clinical characteristics and surgical outcomes of retroperitoneal tumors: a comprehensive data collection from multiple departments[J]. Int J Clin Oncol, 2020, 25: 929-936.
|
| [6] |
Fujimoto N, Kubo T, Hisaoka M, et al. Demographics, management and treatment outcomes of benign and malignant retroperitoneal tumors in Japan[J]. Int J Urol, 2018, 25: 61-67.
|
| [7] |
Brennan MF, Antonescu CR, Moraco N, et al. Lessons learned from the study of 10, 000 patients with soft tissue sarcoma[J]. Ann Surg, 2014, 260: 416-421.
|
| [8] |
Huggett BD, Cates JMM. The Vanderbilt staging system for retroperitoneal sarcoma: a validation study of 6857 patients from the National Cancer Database[J]. Mod Pathol, 2019, 32: 539-545.
|
| [9] |
Pisapia A, Crolla E, Saglioccolo RA, et al. Preoperative diagnosis and surgical treatment for giant retroperitoneal liposarcoma: A case report[J]. Int J Surg Case Rep, 2019, 57: 179-182.
|
| [10] |
Bourouail O, Kada A, Bahou K, et al. Large retroperitoneal ganglioneuroma revealed by a left ovarian endometrioma: A case report[J]. SAGE Open Med Case Rep, 2024, 12: 2050313X241252744.
|
| [11] |
Nirhale DS, Modi V, Kulkarni AA. Giant Retroperitoneal Liposarcoma: A Rare Surgical Occurrence[J]. Cureus, 2024, 16(12): e76192.
|
| [12] |
Marcu D, Iorga L, Diaconu C, et al. Impact of retroperitoneal tumors on the digestive tract(Review)[J]. Exp Ther Med, 2022, 24(6): 711.
|
| [13] |
Gulati V, Swarup MS, Kumar J. Solid Primary Retroperitoneal Masses in Adults: An Imaging Approach[J]. Indian J Radiol Imaging, 2022, 32(2): 235-252.
|
| [14] |
Polat YB, Gultekin MA, Akcay A, et al. Beyond the surface: A comprehensive radiological review of primary retroperitoneal neoplasms[J]. Clin Imaging, 2024, 116: 110340.
|
| [15] |
Carone L, Messana G, Vanoli A, et al. Correlation between imaging and histology in benign solitary retroperitoneal nerve sheath tumors: a pictorial review[J]. Insights Imaging, 2024, 15(1): 132.
|
| [16] |
Feng Y, Zhang W, Luo C. Analysis of the clinical value of multi-slice spiral computed tomography(MSCT), magnetic resonance imaging (MRI) and ultrasound(US) in the diagnosis of retroperitoneal tumors [J]. Transl Cancer Res, 2021, 10(5): 2247-2254.
|
| [17] |
Wilkinson MJ, Martin JL, Khan AA, et al. Percutaneous core needle biopsy in retroperitoneal sarcomas does not influence local recurrence or overall survival[J]. Ann Surg Oncol, 2015, 22: 853-858.
|
| [18] |
Nardi W, Nicolas N, El Zein S, et al. Diagnostic accuracy and safety of percutaneous core needle biopsy of retroperitoneal tumours[J]. Eur J Surg Oncol, 2024, 50(1): 107298.
|
| [19] |
Swallow CJ, Strauss DC, Bonvalot S, et al. Management of primary retroperitoneal sarcoma(RPS) in the adult: an updated consensus approach from the Transatlantic Australasian RPS Working Group[J]. Ann Surg Oncol, 2021, 28: 7873-7888.
|
| [20] |
Nathan H, Raut CP, Thornton K, et al. Predictors of survival after resection of retroperitoneal sarcoma: a population-based analysis and critical appraisal of the AJCC staging system[J]. Ann Surg, 2009, 250(6): 970-976.
|
| [21] |
Giuliano K, Nagarajan N, Canner JK, et al. Predictors of improved survival for patients with retroperitoneal sarcoma[J]. Surgery, 2016, 160(6): 1628-1635.
|
| [22] |
Fairweather M, Raut CP. ASO Author Reflections: Rationale for Organ Resection for Retroperitoneal Sarcomas[J]. Ann Surg Oncol, 2018, 25(Suppl 3): 940-941.
|
| [23] |
Tan MC, Yoon SS. Surgical management of retroperitoneal and pelvic sarcomas[J]. J Surg Oncol, 2015, 111(5): 553-561.
|
| [24] |
Munoz P, Bretcha-Boix P, Artigas V, et al. Surgical Principles of Primary Retroperitoneal Sarcoma in the Era of Personalized Treatment: A Review of the Frontline Extended Surgery[J]. Cancers(Basel), 2022, 14(17): 4091.
|
| [25] |
曲腾飞，何向阳，周斌, 等. 腹膜后肿瘤手术入路及相关技巧[J]. 中华普通外科杂志, 2020, 35(6): 499-501.
|
| [26] |
Álvarez Álvarez R, Manzano A, Agra Pujol C, et al. Updated Review and Clinical Recommendations for the Diagnosis and Treatment of Patients with Retroperitoneal Sarcoma by the Spanish Sarcoma Research Group(GEIS)[J]. Cancers(Basel), 2023, 15(12): 3194.
|
| [27] |
Gamboa AC, Gronchi A, Cardona K. Soft-tissue sarcoma in adults: An update on the current state of histiotype-specific management in an era of personalized medicine[J]. CA Cancer J Clin, 2020, 70(3): 200-229.
|
| [28] |
李智德，陈雄，宋巍, 等. 84例腹膜后肿瘤的临床特点及治疗体会[J]. 新疆医学, 2024, 54(11): 1287-1291, 1295.
|
| [29] |
Bonvalot S, Rivoire M, Castaing M, et al. Primary retroperitoneal sarcomas: a multivariate analysis of surgical factors associated with local control[J]. J Clin Oncol, 2009, 27(1): 31-37.
|
| [30] |
Gronchi A, Lo Vullo S, Fiore M, et al. Aggressive surgical policies in a retrospectively reviewed single-institution case series of retroperitoneal soft tissue sarcoma patients[J]. J Clin Oncol, 2009, 27(1): 24-30.
|
| [31] |
Garcia-Ortega DY, Ortega Jiménez JA, Melendez-Fernandez AP, et al. Does compartmental resection really impact retroperitoneal soft tissue sarcomas? A retrospective analysis from a Single Referral Center[J]. Surg Oncol, 2023, 51: 101997.
|
| [32] |
Guo Q, Zhao J, Du X, et al. Survival outcomes of surgery for retroperitoneal sarcomas: A systematic review and meta-analysis[J]. PLoS One, 2022, 17(7): e0272044.
|
| [33] |
Kira S, Sawada N, Mochizuki T, et al. Utility of Retroperitoneal Laparoscopic Surgery for Retroperitoneal Tumors[J]. JSLS, 2024, 28(4): e2024. 00031.
|
| [34] |
Hou Z, Xie Q, Qiu G, et al. Safety and efficacy of laparoscopic transperitoneal versus retroperitoneal resection for benign retroperitoneal tumors: a retrospective cohort study[J]. Surg Endosc, 2023, 37(12): 9299-9309.
|
| [35] |
Gronchi A, Crago A, Raut CP. Minimally Invasive Surgery for Retroperitoneal Sarcoma: Just Because We Can Does Not Mean We Should[J]. Ann Surg Oncol, 2018, 25(8): 2129-2131.
|
| [36] |
王炯元，姜铨，张启, 等. 腹膜后肿瘤累及重要血管处置中国专家共识(2025版)[J]. 中国实用外科杂志, 2025, 45(5): 485-497.
|
| [37] |
Brennan MF, Antonescu CR, Moraco N, et al. Lessons learned from the study of 10, 000 patients with soft tissue sarcoma[J]. Ann Surg, 2014, 260(3): 416-421.
|
| [38] |
Gronchi A, Strauss DC, Miceli R, et al. Variability in Patterns of Recurrence After Resection of Primary Retroperitoneal Sarcoma (RPS): A Report on 1007 Patients From the Multi-institutional Collaborative RPS Working Group[J]. Ann Surg, 2016, 263(5): 1002-1009.
|
| [39] |
Baldini EH, Wang D, Haas RL, et al. Treatment Guidelines for Preoperative Radiation Therapy for Retroperitoneal Sarcoma: Preliminary Consensus of an International Expert Panel[J]. Int J Radiat Oncol Biol Phys, 2015, 92(3): 602-612.
|
| [40] |
Nussbaum DP, Rushing CN, Lane WO, et al. Preoperative or postoperative radiotherapy versus surgery alone for retroperitoneal sarcoma: a case-control, propensity score-matched analysis of a nationwide clinical oncology database[J]. Lancet Oncol, 2016, 17(7): 966-975.
|
| [41] |
Bonvalot S, Gronchi A, Le Pechoux C, et al. STRASS(EORTC 62092): A phase Ⅲ randomized study of preoperative radiotherapy plus surgery versus surgery alone for patients with retroperitoneal sarcoma[J]. J Clin Oncol, 2019, 37(15): 11001-1.
|
| [42] |
Callegaro D, Raut CP, Ajayi T, et al. Preoperative Radiotherapy in Patients With Primary Retroperitoneal Sarcoma: EORTC-62092 Trial(STRASS) Versus Off-trial(STREXIT) Results[J]. Ann Surg, 2023, 278(1): 127-134.
|
| [43] |
Othman H, Shapiro J, Chung P, et al. Progress in Retroperitoneal Sarcoma Management: Surgical and Radiotherapy Approaches[J]. Semin Radiat Oncol, 2024, 34(2): 164-171.
|
| [44] |
Tseng WW, Barretta F, Conti L, et al. Defining the role of neoadjuvant systemic therapy in high-risk retroperitoneal sarcoma: A multi-institutional study from the Transatlantic Australasian Retroperitoneal Sarcoma Working Group[J]. Cancer, 2021, 127(5): 729-738.
|
| [45] |
D'Ambrosio L, Touati N, Blay JY, et al. Doxorubicin plus dacarbazine, doxorubicin plus ifosfamide, or doxorubicin alone as a first-line treatment for advanced leiomyosarcoma: A propensity score matching analysis from the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group[J]. Cancer, 2020, 126(11): 2637-2647.
|
| [46] |
Demetri GD, von Mehren M, Jones RL, et al. Efficacy and Safety of Trabectedin or Dacarbazine for Metastatic Liposarcoma or Leiomyosarcoma After Failure of Conventional Chemotherapy: Results of a Phase Ⅲ Randomized Multicenter Clinical Trial[J]. J Clin Oncol, 2016, 34(8): 786-793.
|
| [47] |
Chi Y, Fang Z, Hong X, et al. Safety and Efficacy of Anlotinib, a Multikinase Angiogenesis Inhibitor, in Patients with Refractory Metastatic Soft-Tissue Sarcoma[J]. Clin Cancer Res, 2018, 24(21): 5233-5238.
|
| [48] |
Kasper B, Sleijfer S, Litière S, et al. Long-term responders and survivors on pazopanib for advanced soft tissue sarcomas: subanalysis of two European Organisation for Research and Treatment of Cancer(EORTC) clinical trials 62043 and 62072[J]. Ann Oncol, 2014, 25(3): 719-724.
|
| [49] |
Mir O, Brodowicz T, Italiano A, et al. Safety and efficacy of regorafenib in patients with advanced soft tissue sarcoma (REGOSARC): a randomised, double-blind, placebo-controlled, phase 2 trial[J]. Lancet Oncol, 2016, 17(12): 1732-1742.
|